Ask AI
ProCE Banner Events

Monjuvi + Rituximab & Lenalidomide: The First and Only CD19- and CD20-targeted Immunotherapy Combination for 2L+ Follicular Lymphoma Patients (MAT-MON-00929)

Key Takeaways

  • Review FL disease state and unmet needs
  • Examine the study design and efficacy of MONJUVI + R2, a CD19- and CD20-targeted immunotherapy combination
  • Cover safety and dosing of MONJUVI + R2
Time and location

Thursday, April 23, 2026

12:15 PM - 12:45 PM Eastern Time (ET)

Virtual

Acknowledgement

Sponsored By

Incyte

Additional Information

Monjuvi Product Information